Page 10 - Dose Escalation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented in a poster session as part of the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place June 4-8, 2021. These are the first-in-human data of CDX-527, the first candidate developed from Celldex’s

Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting Share Article Trial in progress poster: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors NEW YORK (PRWEB) June 03, 2021 Dracen Pharmaceuticals Inc., announced today that a poster presentation updating the ongoing Phase 1/2a, FIH study of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors will be presented during the trial i...

ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time.

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs   · cancer · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products · Houston, Texas and Tuebingen, Germany, March 17, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a clinical data update from the dose escalation cohorts of the company’s ongoing ...

Posted on 192 Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE 1, RAMSES, ARTEMIS 3, ARC008, ARC011) trials of PALFORZIA ® [Peanut ( Arachis hypogaea) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting held February 26 – March 1, 2021. In patients with p...